

Attachment 6

LIST OF SCIENTIFIC OR ARTISTIC ACHIEVEMENTS WHICH PRESENT A MAJOR CONTRIBUTION
TO THE DEVELOPMENT OF A SPECIFIC DISCIPLINE

**I. INFORMATION ON SCIENTIFIC OR ARTISTIC ACHIEVEMENTS SET OUT IN ART.
219 PARA 1. POINT 2 OF THE ACT**

1. Scientific monograph, pursuant to art. 219 para 1. point 2a of the Act – not applicable
2. **Cycle of scientific articles related thematically, pursuant to art. 219 para 1. point 2b of the Act**

The scientific achievement, which is the basis for applying for the degree of habilitated doctor, is the series of publications listed below, consisting (as of June 6th, 2023) of 9 papers with a total IF of **32.292** (MNiSW = **730** points) according to the year of publication. The cycle consists of 8 original papers and 1 review paper. In all publications I am the corresponding author (marked *), including 7 of them also the first author. The number of citations is based on the Web of Science database (dated June 6th, 2023), after the 'slash' the number of citations without self-citations is given.

[H1] E. Gniazdowska, **P. Koźmiński***, M. Wasek, M. Bajda, J. Sikora, E. Mikiciuk-Olasik, P. Szymański; *Synthesis, physicochemical and biological studies of technetium-99m labeled tacrine derivative as a diagnostic tool for evaluation of cholinesterase level*, Bioorg. Med. Chem., 25 (**2017**) 912-920.

IF₂₀₁₆= **2.454**; . MNiSW₂₀₁₆=**30** points

citations = **7/5**

My contribution to the work: conception of the work, execution of experimental work, analysis, interpretation and elaboration of the obtained results, participation in writing part of the manuscript, final editing of the manuscript and preparation of subsequent responses to the reviewers' comments.

[H2] E. Gniazdowska, **P. Koźmiński***, P. Halik, M. Bajda, K. Czarnecka, E. Mikiciuk-Olasik, K. Masłowska, Z. Rogulski, Ł. Cheda, K. Kilian, P. Szymański; *Synthesis, physicochemical and biological evaluation of tacrine derivative labeled with technetium-99m and gallium-68 as a prospective diagnostic tool for early diagnosis of Alzheimer's disease*. Bioorg. Chem. 91 (**2019**) 103136.

IF₂₀₁₈ =**3.926** MNiSW₂₀₁₈=**100** points

citations = **6/5**

My contribution to the work: concept of the work, execution of the 'chemical' part of the experimental work (synthesis of radioconjugates, characterization of physico-chemical properties, in vitro stability studies), participation in the preparation and editing of the text of the publication. I also prepared responses for reviewers.

[H3] P. Koźmiński*, D.Niedziałek, G. Wieczorek, P.K. Halik, K. Czarnecka, A. Rogut, Ł. Cheda, Z. Rogulski, P. Szymański, E. Gniazdowska; *New imaging modality of COVID-19 pneumonia developed on the basis of Alzheimer's disease research*. Int. J. Mol. Sci. **2022**, 23, 8405.

IF₂₀₂₁= **6.208** MNiSW₂₀₂₁=**140** points

citations = **none**

My contribution to the work: defining the scientific goal, planning and performing the 'chemical' part of the research, as well as analysis and interpretation of the results, participating in the preparation of the manuscript and I also prepared responses for reviewers.

[H4] P. Koźmiński*, W. Gawęda, M. Rzewuska, A. Kopatys, S. Kujda, M. K. Dudek, P. K. Halik, L. Królicki, E.Gniazdowska; *Physicochemical and Biological Study of ^{99m}Tc and ⁶⁸Ga Radiolabelled Ciprofloxacin and Evaluation of [^{99m}Tc]Tc-CIP as Potential Diagnostic Radiopharmaceutical for Diabetic Foot Syndrome Imaging*. Tomography **2021**, 7, 829-842.

IF₂₀₂₀ =**3.358** MNiSW₂₀₂₀=**40** points

citations = **4/3**

My contribution to the work: proposing the research concept, carrying out research under my supervision as part of the master's thesis of a student of the Faculty of Physics at the University of Warsaw (Weronika Maliszewska (Gawęda)), analysis and interpretation of the results, preparation of the manuscript and subsequent responses to the reviewers' comments.

[H5] P. Koźmiński*, M. Rzewuska, A. Piądtowska, P. K. Halik, L., E.Gniazdowska; *Synthesis, physicochemical and in vitro biological evaluation of ^{99m}Tc-cefepime*

radioconjugates, and development of DTPA-cefepime single vial kit formulation for labelling with technetium-99m. J. Radioanal. Nucl. Chem. **2022**, 331, 2883–2894.

IF₂₀₂₁ = **1.754** MNiSW₂₀₂₁ = **40** points

citations = **1/0**

My contribution to the work: proposing the concept of research, conducting research as part of the master's thesis of a student of the Faculty of Physics at the University of Warsaw (Agata Piądtowska) under my supervision, analysis and interpretation of the results obtained, and preparation of the manuscript and subsequent responses to the reviewers' comments.

[H6] P. Koźmiński*, K. Żelechowska-Matysiak, E. Gniazdowska; *Synthesis and physicochemical properties of cefepime derivatives suitable for labelling with gallium-68*. Appl. Sci. **2023**, 13, 5019.

IF₂₀₂₀ = **2.838** MNiSW₂₀₂₁ = **100** points

citations = **none**

My contribution to the work: proposing the research concept, carrying out research as part of the master's thesis of a student of the Faculty of Physics of the University of Warsaw (Kinga Żelechowska-Matysiak) under my supervision, analysis, and interpretation of the results obtained, and preparation of the manuscript and as well as responses to the reviewers' comments.

[H7] P. Koźmiński*, P. Halik, R. Chesori, E. Gniazdowska; *Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers*. Int. J. Mol. Sci. **2020**, 21, 3483.

IF₂₀₂₀ = **5.923** MNiSW₂₀₂₀ = **140** points

citations = **95/93**

My contribution to the work: preparation of the publication outline, literature review, preparation and submission of the manuscript. I also prepared responses for reviewers.

[H8] P. Koźmiński*, P. K. Halik, R. Chesori, E. Gniazdowska; *Common Shortcomings in Study on Radiopharmaceutical Design Research: A Case Study of ^{99m}Tc-Labelled Metxotrexate*. Molecules **2021**, 26, 5862.

IF₂₀₂₀ = **4.412** MNiSW₂₀₂₀ = **100** points

citations = **1/1**

My contribution to the work: defining the purpose and concept of the research, planning the experimental work, analysis and interpretation of the results, preparation and submission of the manuscript as well as responses to the reviewers' comments.

[H9] P. Koźmiński*, M. Gumiela, R. Walczak, K. Wawrowicz, A. Bilewicz; *A semi-automated module for the separation and purification of ^{99m}Tc from simulated molybdenum target.* J. Radioanal. Nucl. Chem. **2021**, 328, 1217–1224.

IF₂₀₂₀ = **1.371** MNiSW₂₀₂₀ = **40** points

citations = **2/2**

My contribution to the work: defining the purpose and concept of the research, participation in the experimental work, analysis and interpretation of the results, preparation and editing of the text of the publication, submitting the manuscript and subsequent responses to the reviewers' comments.

3. List of completed original project, engineering and design, technological or artistic achievements, pursuant to art. 219 para 1. point 2c of the Act - not applicable

II. INFORMATION ON SCIENTIFIC OR ARTISTIC ACTIVITY

1. List of published scientific monographs (including the monographs not mentioned in section I.1) – not applicable
2. **List of published chapters in scientific monographs**

A1. **P. Koźmiński***, E. Gniazdowska*, K. Bańkowski, H.-J. Pietzsch, *^{99m}Tc-labelled vasopressin peptide as a potential radiopharmaceutical for small-cell lung cancer (SCLC) imaging*, Proceedings of 7th International Symposium on Technetium and other Radiometals in Chemistry and Medicine TERACHEM-2010, Italy, (p. 337-338). SGE – Padova, 2010.

MNiSW₂₀₀₉ = **5** points

A2. E. Gniazdowska, **P. Koźmiński**, K. Bańkowski, H.-J. Pietzsch, *^{99m}Tc-labelled vasopressin peptide, synthesis and in vitro and in vivo evaluation*, Proceedings of 2nd

International Conference on Application of Radiotracers in Chemical, Environmental and Biological Sciences (ARCEBS-10), India, (p. 351-353). Saha Institute of Nuclear Physics – Kolkata, 2010.

MNiSW₂₀₀₉ = 5 points

A3. A. Bilewicz, L. Fuks, E. Gniazdowska, A. Kasperek, **P. Koźmiński**, S. Krajewski, E. Leszczuk, M. Łyczko, *Badania chemiczne w instytucie chemii i techniki jądrowej nad projektowaniem i syntezą nowych radiofarmaceutyków* (s. 2-13), *Postępy Techniki Jądrowej*, 56, Z.2, 2012, ISSN 0551-6846 Warszawa.

MNiSW₂₀₁₁ = 5 points

A4. M. Trojanowicz, **P. Koźmiński**, *Nowe metodologie pomiarowe w laboratoryjnej analizie przepływowej*, P. Kościelaniak, M. Trojanowicz, *Analiza przepływowa - metody i zastosowania*, 2005, Wydawnictwo Uniwersytetu Jagiellońskiego, ISBN 83-223-2093-4.

MNiSW₂₀₀₄ = 5 points

3. Information about membership in editorial boards preparing scientific monographs for publication- - – not applicable
4. **List of articles published in scientific journals (including the articles not mentioned in section I.2).**

after obtaining the doctoral degree:

A1. P.K. Halik, **P. Koźmiński**, J. Matalińska, P.F.J. Lipiński, A. Misicka, E. Gniazdowska; *In Vitro Biological Evaluation of Aprepitant Based ¹⁷⁷Lu-Radioconjugates*. *Pharmaceutics* **2022**, 14, 607.

IF₂₀₂₁ = 6.525 MNiSW₂₀₂₁ = 100 points
citations = 2/2

A2. J. Matalińska, K. Kosińska, P.K. Halik, **P. Koźmiński**, P.F.J. Lipiński, E. Gniazdowska, A. Misicka; *Novel NK1R-Targeted ⁶⁸Ga-/¹⁷⁷Lu-Radioconjugates with Potential Application against Glioblastoma Multiforme: Preliminary Exploration of Structure–Activity Relationships*. *Int. J. Mol. Sci.* **2022**, 23, 1214.

IF₂₀₂₁ = 6.209 MNiSW₂₀₂₁ = 140 points
citations = 5/4

A3. A. Apostolopoulou, A. Chiotellis, E.-A. Salvanou, K. Makrypidi, C.Tsoukalas, F.Kapiris, M. Paravatou-Petsotas, M. Papadopoulos, I. C. Pirmettis, **P. Koźmiński**, P. Bouziotis; *Synthesis and In Vitro Evaluation of Gold Nanoparticles Functionalized with Thiol Ligands for Robust Radiolabeling with ^{99m}Tc*. *Nanomaterials* **2021**, 11, 2406.

IF₂₀₂₀ = 5.076 MNiSW₂₀₂₀ = **70** points
citations = **3/3**

A4. P. Halik, **P. Koźmiński**, E. Gniazdowska; *Perspectives of Methotrexate-Based Radioagents for Application in Nuclear Medicine*. *Mol. Pharmaceutics* **2021**, 18, 33-43.

IF₂₀₂₀ = 4.939 MNiSW₂₀₂₀ = **140** points
citations = **1/0**

A5. P. Halik, P. Lipiński, J. Matalińska, **P. Koźmiński**, A. Misicka, E. Gniazdowska; *Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors*. *Molecules* **2020**, 25, 3756

IF₂₀₂₀ = 4.412 MNiSW₂₀₂₀ = **100** points
citations = **9/6**

A6. A. Majkowska-Pilip, **P. Koźmiński**, A. Wawrzynowska, T. Budlewski, B. Kostkiewicz, E. Gniazdowska; *Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with ^{99m}Tc and ¹⁷⁷Lu as Potential Receptor Radiopharmaceuticals*. *Molecules* **2018**, 23, 2542.

IF₂₀₁₇ = 3.098 MNiSW₂₀₁₇ = **30** points
citations = **8/6**

A7. L. Dziawer, **P. Koźmiński**, S. Męczyńska-Wielgosz, M. Pruszyński, M. Łyczko, B. Wąs, G. Celichowski, J. Grobelny, J. Jastrzębski, A. Bilewicz; *Gold nanoparticle bioconjugates labelled with ²¹¹At for targeted alpha therapy*. *RSC Adv.* 7 (**2017**) 41024–41032.

IF₂₀₁₆ = 3.108 MNiSW₂₀₁₆ = **30** points
citations = **36/36**

A8. A. Piotrowska, S. Męczyńska-Wielgosz, A. Majkowska-Pilip, **P. Koźmiński**, G. Wójciuk, E. Cędrowska, F. Bruchertseifer, A. Morgenstern, M. Kruszewski, A. Bilewicz; *Nanozeolite bioconjugates labeled with ²²³Ra for targeted alpha therapy*. *Nucl. Med. Biol.*, 47 (**2017**) 10-18.

IF₂₀₁₆ = 2.426 MNiSW₂₀₁₆ = **35** points

citations =**38/37**

A9. **P. Koźmiński***, E. Gniazdowska; *Synthesis and in vitro/in vivo evaluation of novel mono- and trivalent technetium-99m labelled Ghrelin peptide complexes as potential diagnostic radiopharmaceuticals*. Nucl. Med. Biol., 42 (2015) 28-37.

IF₂₀₁₄ = 2.412 **MNiSW₂₀₁₄ = 30** points
citations =**15/15**

A10. E. Gniazdowska, **P. Koźmiński**, K. Bańkowski, W. Łuniewski, L. Królicki; *Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer*. Eur. J. Med. Chem. 87 (2014) 493-499.

IF₂₀₁₃ = 3.432 **MNiSW₂₀₁₃ = 40** points
citations =**8/8**

A11. Ewa Gniazdowska, **P. Koźmiński**, Krzysztof Bańkowski, and Paweł Ochman; *^{99m}Tc-labeled Vasopressin Peptide as a Radiopharmaceutical for Small-Cell Lung Cancer (SCLC) Diagnosis*. J. Med. Chem., 57 (2014) 5986-5994.

IF₂₀₁₃ = 5.614 **MNiSW₂₀₁₃ = 45** points
citations =**14/14**

A12. E. Gniazdowska, **P. Koźmiński**, L. Fuks; *Synthesis, radiochemistry and stability of the conjugates of technetium-99m complexes with Substance P*. J. Radioanal. Nucl. Chem., 298 (2013) 1171-1177.

IF₂₀₁₂ = 1.467 **MNiSW₂₀₁₂ = 20** points
citations =**7/5**

before obtaining the doctoral degree:

A13. L. Fuks, E. Gniazdowska, **P. Koźmiński**, I. Herdzik-Koniecko; *Technetium(I) Tricarbonyl Complexes - Potential Precursors Of The Radiopharmaceuticals. Part II: Phenethylbiguanide (Phenformin)*. J. Radioanal. Nucl. Chem., 292 (2012) 395-399.

IF₂₀₁₁ = 1.520 **MNiSW₂₀₁₁ = 20** points
citations =**4/4**

A14. L. Fuks, E. Gniazdowska, **P. Kozminski**, J. Mieczkowski; *Technetium(I) tricarbonyl complexed with the n-heterocyclic aldehyde thiosemicarbazones - potential precursor of the radiopharmaceuticals*. J. Radioanal. Nucl. Chem., 292 (2012) 255-259.

IF₂₀₁₁ = 1.520 **MNiSW₂₀₁₁ = 20** points
citations =**5/5**

A15. **P. Koźmiński***, E. Gniazdowska, L. Fuks and A. Oszczak; *Labelling of peptides with technetium-99m complexes through the modified C-terminal group*. J. Radioanal. Nucl. Chem., 292 (2012) 67-74.

IF₂₀₁₁ = 1.520 **MNiSW₂₀₁₁ = 20** points
citations =**6/3**

A16. D. Papagiannopoulou, C. Tsoukalas, G. Makris, C. P. Raptopoulou, V. Psyharis, L. Leondiadis, E. Gniazdowska, **P. Kozminski**, L. Fuks, M. Pelecanou, I. Pirmettis, M. S. Papadopoulos; *Histidine derivatives as tridentate chelators for the fac-[M^I(CO)₃] (Re, ^{99m}Tc, ¹⁸⁸Re) core: Synthesis, structural characterization, radiochemistry and stability*. Inorg. Chim. Acta, 378 (2011) 333–337.

IF₂₀₁₀ = 1.899 **MNiSW₂₀₁₀ = 27** points
citations =**18/18**

A17. J.-U. Künstler, R. Bergmann, E. Gniazdowska, **P. Koźmiński**, M. Walther, H.-J. Pietzsch, *Impact of functionalized coligands on the pharmacokinetics of ^{99m}Tc(III)'4+1'mixed-ligand complexes conjugated to bombesin*. J. Inorg. Biochem., 105 (2011) 1383–1390.

IF₂₀₁₀ = 3.317 **MNiSW₂₀₁₀ = 32** points
citations =**9/7**

A18. **P. Koźminski***, E. Gniazdowska, L. Fuks, S. Kowalska; *'2+1' Tricarbonyltechnetium (I) / tricarbonylrhenium(I) mixed-ligand complexes with methyl thiosalicylate and isocyanide ligands as potential precursors of radiopharmaceuticals*. Appl. Radiat. Isotopes, 69 (2011) 436–442.

IF₂₀₁₀ = 0.999 **MNiSW₂₀₁₀ = 32** points
citations =**11/8**

A19. L. Fuks, E. Gniazdowska, **P. Kozminski**, M. Lyczko, J. Mieczkowski, J. Narbutt; *'2+1' Tricarbonyltechnetium(I) and-rhenium(I) mixed-ligand complexes with N-methylpyridine-2-carboxamide and isocyanide or imidazole ligands-potential precursors of radiopharmaceuticals*. Appl. Radiat. Isotopes, 68 (2010) 90–95.

IF₂₀₀₉ = 1.094 **MNiSW₂₀₀₉ = 24** points
citations =**12/9**

A20. L. Fuks, E. Gniazdowska, **P. Koźmiński***; *Tricarbonylrhenium(I) complexes with anionic ligands containing S and O donor atoms – potential radiopharmaceutical precursors*. Polyhedron, 29 (2010) 634–63.

IF₂₀₀₉ = 2.207 **MNiSW₂₀₀₉ = 24** points
citations =**11/9**

before 2007 (before employment at IChTJ)

A21. **P. Koźmiński**, A.M.O. Brett, Anthocyanin monitoring in four red grape skin extract varieties using RP-HPLC-ED, *Anal. Lett.*, 41 (2008) 662-675.

IF₂₀₀₇ = **1.362** MNiSW₂₀₀₇ = **15** points
citations = **12/12**

A22. **P. Koźmiński**, A.M.O. Brett, Reversed-phase high performance liquid chromatography with electrochemical detection of anthocyanins, *Anal. Lett.*, 39 (2006) 2687-2697.

IF₂₀₀₅ = **1.036** MNiSW₂₀₀₅ = **15** points
citations = **9/8**

A23. M. Trojanowicz, **P. Kozminski**, H. Dias, C.M.A. Brett; *Batch-injection stripping voltammetry (tube-less flow-injection analysis) of trace metals with on-line sample pretreatment*. *Talanta* 68 (2005) 394-40.

IF₂₀₀₄ = **2.532** MNiSW₂₀₀₅ = **24** points
citations = **31/31**

5. List of project, engineering and design as well as technological achievements (including the achievements not mentioned in section I.3) - not applicable.
6. List of public realizations of works of art (including the works not mentioned in section I.3) - not applicable.
7. **Information on presentations given at national or international scientific or arts conferences, including a list of lectures delivered upon invitation and plenary lectures.**

RESEARCH RESULTS PRESENTED AS ORAL PRESENTATIONS

A1. **P. Koźmiński**, *Synthesis and in vitro studies of new radioconjugates based on selected antibiotics radiolabelled with ⁶⁸Ga/^{99m}Tc for diagnosis of diabetic foot infections*; Young investigators Symposium, May, 16th 2018, Otwock-Świerk, Poland.

A2. **P. Koźmiński**, Ł. Janiszewska, M. Pruszyński, B. Wąs, J. Jastrzębski, J. Choiński, A. Stolarz, M. Sitarz, K. Szkliniarz, J. Grobelny, G. Celichowski, A. Bilewicz; *Gold nanoparticle – conjugates as a carrier for ²¹¹At in alpha particle therapy*, 10th

International Symposium on Targeted Alpha Therapy (TAT-10) 30.05-02.06.2017, Kanazawa, Japan.

A3. **P. Koźmiński**, Ł. Janiszewska, M. Pruszyński, A. Stolarz, A. Trzcińska, K. Szkliniarz, B. Wąs, A. Bilewicz, P. Bouziotis, M.-A. Karageorgou, S. Xanthopoulos; *Gold Nanoparticle bioconjugates labelled with ^{211}At – new radiopharmaceuticals for alpha immunotherapy*, COST TD1004 Final Annual Meeting, Serbian Academy of Sciences and Arts, 10-11 September 2015, Belgrade, Serbia.

A4. Ł. Janiszewska, **P. Koźmiński**, M. Pruszyński, A. Bilewicz, J. Jastrzębski, J. Choiński, A. Stolarz, A. Trzcińska, K. Szkliniarz, W. Zipper; *Gold Nanoparticle–Substance P(5-11) Conjugate as a Carrier for ^{211}At in Alpha Particle Therapy*, 9th Symposium on Targeted Alpha Therapy, 19-21 May 2015 Warsaw, Poland.

A5. **P. Koźmiński**, E. Gniazdowska; *Znakowanie greliny kompleksami technetu-99m typu '2+1' i '4+1'*, XIII Convention of the Polish Society of Nuclear Medicine, 19-22 September 2012, Kielce, Poland.

A6. **P. Koźmiński**, E. Gniazdowska; *Technetium-99m(I), '2+1', and Technetium-99m(III), '4+1', mixed-ligand complexes conjugated to ghrelin*, 30th International Symposium "Radioactive Isotopes in Clinical Medicine and Research", 11-14 January 2012, Bad Hofgastein, Austria.

A7. **P. Koźmiński**, E. Gniazdowska, L. Fuks; *Tricarbonyltechnetium(I) Complexes With Anionic Bidentate Ligand With S And O Donor Atoms – Methyl Thiosalicylate*, 29th International Symposium "Radioactive Isotopes in Clinical Medicine and Research", 15-20 January 2010, Bad Hofgastein, Austria.

A8. E. Gniazdowska, **P. Koźmiński**; *Towards Tc(III)- and Re(III)-labelled peptides with tunable lipophilicity*, Workshop – POLRADPHARM ToK Project – Warsaw, May 17th 2008, Warsaw, Poland.

A9. **P. Koźmiński**; *Reversed-Phase High-Performance Liquid Chromatography with Electrochemical Detection of Anthocyanins*, Novel Technology for Controlling Wine Production and Quality, 23 – 24 March 2006, Ljubljana, Slovenia.

A10. **P. Koźmiński**; *Alcoholic strength by volume*, Novel Technology for Controlling Wine Production and Quality, 17-21 June 2005, Viseu, Portugal.

RESEARCH RESULTS, PRESENTED AS POSTERS (only conferences where P. Koźmiński was the person presenting the poster are listed):

A1. **P. Koźmiński**, G. Wieczorek, E. Gniazdowska, Ł. Cheda, P. Hamankiewicz, Z. Rogulski, D. Niedziałek; *Synthesis of new azobenzene derivatives radiolabelled with gallium-68 as new imaging agents for the diagnosis of Alzheimer's disease*, International Symposium on Trends in Radiopharmaceuticals (ISTR-2023) 17-21.04.2023, Vienna, Austria.

A2. **P. Koźmiński**, M. Gumiela, A. Bilewicz; *Separation and purification of ^{99m}Tc from simulated target*, Mo-99 International Symposium, 5-7.10.2022, Vienna, Austria.

A3. F. Biscarini, C. Bortolotti, **P. Koźmiński**, D. Niedziałek, P. Reschiglian, B. Roda, F. Stefaniak, G. Wieczorek, A. Zattoni; *Dissociation of amyloid aggregates with photo-switchable molecular levers*, 6th Visegrad Symposium on Structural Systems Biology (VSSSB), 19-21 June 2016, Warsaw, Poland.

A4. E. Gniazdowska, **P. Koźmiński**, E. Mikiciuk-Olasik, J. Sikora, P. Szymański; *Synthesis, radiolabelling, in vitro and vivo behaviour of tacrine derivatives*, 17th Radiochemical Conference, RadChem 2014, 11-16 May 2014, Mariánské Lázně, Czech Republic.

A5. **P. Koźmiński**, E. Gniazdowska; *Ghrelin peptide labelled with technetium-99m complexes a potential diagnostic radiopharmaceuticals*, 20th International Symposium on Radiopharmaceutical Sciences - ISRS 2013, 12-17 May 2013, Jeju, Republic of Korea.

A6. **P. Koźmiński**, E. Gniazdowska; *Ghrelin peptide labelled with mono- or trivalent technetium-99m complexes*, IX Warszawskie Seminarium Doktorantów Chemików - ChemSession'12, May 10th 2012, Warsaw, Poland.

A7. **P. Koźmiński**, E. Gniazdowska; *Ghrelin peptide labelled with mono- or trivalent technetium-99m complexes*, 19th International Symposium on Radiopharmaceutical Sciences - ISRS 2011, 28.08-2.09 2011, Amsterdam, Netherlands.

A8. **P. Koźmiński**, E. Gniazdowska, L. Fuks; *Znakowanie peptydów kompleksami technetu-99m poprzez zmodyfikowaną C-końcową grupę karboksylową*, VIII Warszawskie Seminarium Doktorantów Chemików - ChemSession'11, May 13th 2011, Warsaw, Poland.

A9. **P. Koźmiński**, E. Gniazdowska, L. Fuks; *Znakowanie peptydów kompleksami technetu-99m poprzez zmodyfikowaną C-końcową grupę karboksylową*, Ogólnopolska Konferencja Radiofarmaceutyczna, 12-13 May 2011, Łódź, Poland.

A10. **P. Kozminski**, E. Gniazdowska, K. Bankowski, H.-J. Pietzsch; *^{99m}Tc-labelled vasopressin peptide, synthesis and in vitro and in vivo evaluation*, 2nd International Conference on Application of Radiotracers in Chemical, Environmental and Biological Sciences (ARCEBS-10), 7-13 November 2010, Kolkata, India.

A11. **P. Koźmiński**, E. Gniazdowska, L. Fuks; *Tricarbonyltechnetium(I) complexes with anionic bidentate ligand with S and O donor atoms – methyl thiosalicylate*, VII Warszawskie Seminarium Doktorantów Chemików - ChemSession'10, May 14th 2010, Warsaw, Poland.

A12. **P. Koźmiński**, E. Gniazdowska, L. Fuks; *Tricarbonyltechnetium(I)/Rhenium(I) Complexes With Neutral Bidentate Ligands With S And O Donor Atoms*, 10th FIGIPAS Meeting in Inorganic Chemistry, 30.06-05.07 2009, Palermo, Italy.

A13. E. Gniazdowska, **P. Koźmiński**, L. Fuks, S. Kowalska; *Trikarbonylkowe kompleksy technetu(I) i renu(I) z bidentnymi ligandami zawierającymi siarkę i tlen jako atomy donorowe*, V Krajowa Konferencja Radiochemii i Chemii Jądrowej, 24-27 May 2009, Cracow, Poland.

A14. E. Gniazdowska, **P. Koźmiński**, K. Bańkowski, H.-J. Pietzsch; *Znakowanie Wazopresyny Mieszanymi Kompleksami Tc-99m „Typu 4+1”*, VI Warszawskie Seminarium Doktorantów Chemików - ChemSession'09, May 15th 2009, Warsaw, Poland.

A15. **P. Kozminski**, E. Gniazdowska, L. Fuks, J. Mieczkowski; *Tricarbonyltechnetium(I)/rhenium (I) complexes with neutral bidentate ligands with N, S, O donor atoms and monodentate isonitrile ligand*, 4th EuCheMS Conference on Nitrogen Ligands in Coordination Chemistry, Metal-Organic Chemistry, Bioinorganic Chemistry and Homogeneous Catalysis, 23-29 August 2008, Garmisch-Partenkirchen, Germany.

A16. E. Gniazdowska, **P. Koźmiński**, H.-J.Pietzsch, J.-U. Künstler, J. Mieczkowski; *Nowe ligandy typu RNS₃ do syntezy radiofarmaceutyków technetu(III) i renu(III)*, 50 Jubileuszowy Zjazd Polskiego Towarzystwa Chemicznego i 11 Międzynarodowa Konferencja Chemii Środowiska, 9-12 September 2007, Toruń, Poland.

A17. **P. Koźmiński**, P. Janeiro, A. M. Oliveira Brett; *Determination of anthocyanins in red grape skin extracts by RP-HPLC-ED and BIA-ED*, 10th International Conference On Flow Analysis – Flow X, 3-8 September 2006, Porto, Portugal.

A18. **P. Koźmiński**, A. M. Oliveira Brett; *Reversed-phase high-performance liquid chromatography with electrochemical detection for anthocyanins*, 11th International Conference on Electroanalysis, ESEAC, 11-15 June 2006, Bordeaux, France.

A19. P. Janeiro, **P. Kozminski**, A. M. Oliveira Brett; *RP-HPLC with electrochemical detection of flavonoids*, SPQ-Analítica'05, 27-28 October 2005, Coimbra, Portugal.

A20. P. Janeiro, **P. Kozminski**, A. M. Oliveira Brett; *Analysis of flavonoids by RP-HPLC with electrochemical detection*, XVIII International Symposium on Bioelectrochemistry and Bioenergetics of the Bioelectrochemical Society (BES) and 3rd Spring Meeting: Bioelectrochemistry of the International Society of Electrochemistry (ISE), 19-24 June 2005, Coimbra, Portugal.

PRESENTATIONS OF RESULTS AT OTHER CONFERENCES

A1. E. Gniazdowska, K. Masłowska, P. Halik, **P. Koźmiński**, D. Tymecka, P. Redkiewicz, A. Misicka; *Radiolabeled inhibitors of VEGF-A165/NRP-1 complex for pathological angiogenesis imaging*; International Symposium on Trends in Radiopharmaceuticals (ISTR-2023) 17-21.04.2023, Vienna, Austria.

A2. A. Apostolopoulou, K. Makrypidi, E-A. Salvanou, A. Chiotellis, I. Pirmettis, M. Papadopoulos, C. Tsoukalas, **P. Koźmiński**, P. Bouziotis; *Functionalization of gold nanoparticles with thiol ligands and radiolabeling with ^{99m}Tc*, 18th Hellenic Symposium on Medicinal Chemistry, 25-27 February 2021, Athens, Greece.

A3. P. K. Halik, E. Gniazdowska, **P. Koźmiński**, P. Lipiński, J. Matalińska; *In vitro NK1R affinity evaluation of novel radioconjugates based on peptide antagonist SPANTIDE I and Ga-68/Lu-177 theranostic-like isotopes for glioma cancer*, International Symposium on Trends in Radiopharmaceuticals (ISTR-2019), 28.10–1.11 2019, Vienna, Austria.

A4. M. Gumiela, **P. Koźmiński**, A. Bilewicz; *Isolation of ^{99m}Tc from the gamma irradiated ¹⁰⁰Mo target*, 23rd International Symposium on Radiopharmaceutical Sciences - ISRS-2019, 26-31 May 2019, Beijing China.

A5. P. Halik, **P. Koźmiński**, E. Gniazdowska, M. Chojnowski, A. Kopatys, L. Królicki; *Preclinical evaluation of new radiopreparations based on selected antibiotics*

radiolabelled with ^{99m}Tc for diagnosis of diabetic foot infections, The European Nuclear Young Generation Forum (ENYGF) 23-27 June 2019, Ghent, Belgium.

A6. K. Żelechowska-Matysiak, B. Brzozowska-Wardecka, **P. Koźmiński**; *Synteza i badanie właściwości fizykochemicznych radiokoniugatu gal-68 – cefepim jako potencjalnego radiofarmaceutyku do diagnostyki PET infekcji bakteryjnych*, XVI Warszawskie Seminarium Doktorantów Chemików - ChemSession'19, June 7th 2019, Warsaw, Poland.

A7. K. Wawrowicz, M. Gumiela, **P. Koźmiński**, A. Bilewicz; *Cykliczne wydzielanie ^{99m}Tc z naświetlonych promieniowaniem γ tarcz ^{100}Mo* , XVI Warszawskie Seminarium Doktorantów Chemików - ChemSession'19, June 7th 2019, Warsaw, Poland.

A8. G. Wieczorek, **P. Kozminski**, Z. Bednarikova, Z. Gazova, D. Niedzialek; *New small-molecule agents for a controlled degradation amyloid-based biomaterials*, Gordon Research Conference on Self-Assembly and Supramolecular Chemistry, 19-24 May 2019, Les Diablerets, Switzerland.

A9. G. Wieczorek, **P. Kozminski**, Z. Bednarikova, Z. Gazova, D. Niedzialek; *New small-molecule agents for a controlled degradation amyloid-based biomaterials*, Frontiers in polymer science, 5-8 May 2019 Budapest, Hungary

A10. W. Wargocka, Ł. Cheda, P. Hamankiewicz, P. Halik, **P. Koźmiński**, E. Gniazdowska, Z. Rogulski; *Badania in vivo biodystrybucji ^{68}Ga -DOTA-(NH(CH₂)₉Tac) w modelu zwierzęcym*, XV Warszawskie Seminarium Doktorantów Chemików - ChemSession'18, June 8th 2018, Warsaw, Poland.

A11. P. Halik, E. Gniazdowska, **P. Koźmiński**, M. Bajda, K. Czarnecka, P. Szymański, Z. Rogulski, Ł. Cheda; *Poszukiwania nowych radiobiokoniugatów takryny znakowanych galem-68 o potencjalnym zastosowaniu we wczesnej diagnostyce choroby Alzheimera*, XV Warszawskie Seminarium Doktorantów Chemików - ChemSession'18, June 8th 2018, Warsaw, Poland.

A12. P. Halik, E. Gniazdowska, **P. Koźmiński**, K. Czarnecka, P. Szymański, Z. Rogulski, Ł. Cheda, M. Bajda; *Poszukiwania nowych radiobiokoniugatów znakowanych ^{68}Ga i ^{99m}Tc o potencjalnym zastosowaniu we wczesnej diagnostyce choroby Alzheimera*, XI Multidyscyplinarna Konferencja Nauki o Leku-MKNOL 2018, 14-16 November 2018, Warsaw, Poland.

A13. M. Gumiela, **P. Koźmiński**, A. Bilewicz; *Isolation of ^{99m}Tc from the gamma/proton irradiated ^{100}Mo target*, The Third International Symposium on

Technetium and other Radiometals in Chemistry and Medicine, 26-29 September 2018, Bressanone, Italy.

A14. Z. Bednáriková, Z. Gažová, **P. Koźmiński**, I. Krizbai, D. Niedziałek, M. Sántha, G. Wiczorek, I. Wilhelm; *Structure and dynamics of β -amyloid proto-fibrils as a basis for rational drug design against Alzheimer's Disease*, 10th International Conference "Structure and Stability of Biomacromolecules", SSB, 3-7 September 2017 Kosice, Slovak Republic.

A15. A. Bilewicz, Ł. Dziawer, **P. Koźmiński**; *Biocojugates of gold nanoparticles with trastuzumab labelled with ^{211}At for internal alpha therapy*, 22nd International Symposium on Radiopharmaceutical Sciences - ISRS 2017, 14-19 May 2013, Dresden, Germany.

A16. M. Tsitopoulou., M. Karageorgou, **P. Koźmiński**, S. Xanthopoulos, Z. Sideratou, A. Bilewicz, G. Rassias, C. Tsoukalas, P. Bouziotis; *Radiolabeling of Gold nanoparticles (GNPs) with ^{68}Ga : in vitro/in vivo evaluation*, 22nd Panhellenium Conference of Chemistry, 2-4 December 2016, Thessaloniki, Greece

A17. A. Majkowska-Pilip, E. Gniazdowska, A. Rawicz-Galińska, M. Bednarczyk, **P. Koźmiński**, T. Budlewski, A. Bilewicz; *Physicochemical and biological characterization of SubstanceP fragments labeled with ^{177}Lu* , 29th Annual Congress of the European Association of Nuclear Medicine - EANM'16, 15-19 October, Barcelona, Spain.

A18. E. Leszczuk, , L. Janiszewska, **P. Koźmiński**, A. Morgenstern, F. Bruchertseifer, A. Bilewicz; *Nanoparticle bioconjugates labeled with alpha emitters*, 2nd International Symposium on TECHNETIUM and other RADIOMETALS in CHEMISTRY and MEDICINE, 10-13 September 2014, Bressanone, Italy.

A19. M. Gumiela, E. Gniazdowska, **P. Koźmiński**, A. Bilewicz; *A new simple way separation of ^{99m}Tc from ^{100}Mo target*, 2nd International Symposium on TECHNETIUM and other RADIOMETALS in CHEMISTRY and MEDICINE, 10-13 September 2014, Bressanone, Italy.

A20. M. Gumiela, E. Gniazdowska, **P. Koźmiński**, A. Bilewicz; *Wydzielanie Tc-99m z aktywowanej w cyklotronie tarczy molibdenowej*, X Warszawskie Seminarium Doktorantów Chemików - ChemSession'13, May 17th 2013, Warsaw, Poland.

A21. M. Gumiela, E. Gniazdowska, **P. Koźmiński**, A. Bilewicz; *Wydzielanie Tc-99m z aktywowanej w cyklotronie tarczy molibdenowej*, VI Krajowa Konferencja Radiochemii i Chemii Jądrowej, 21 - 24 April 2013 roku, Cracow-Przegorzały, Poland.

A22. E. Gniazdowska, **P. Koźmiński**, K. Bańkowski, H.-J. Pietzsch; *Vasopressin Peptide (AVP) Labeled with „4+1”Mixed-Ligand Technetium*, 10th FIGIPAS Meeting in Inorganic Chemistry, 30.06-05.07 2009, Palermo, Italy.

A23. E. Gniazdowska, **P. Koźmiński**, L. Fuks; *Znakowanie Cząsteczek Biologicznie Czynnych Diagnostycznymi/Terapeutycznymi Radionuklidami*, V Krajowa Konferencja Radiochemii i Chemii Jądrowej, 24-27 May 2009, Cracow, Poland.

A24. E. Gniazdowska, **P. Koźmiński**, J.-U. Kuentler, H.-J. Pietzsch; *Towards Tc(III)- or Re(III)-labelled peptides with tunable lipophilicity*, Workshop on Radionuclides And Their Carriers For Medical and Industrial Applications, 21 November 2007, Warsaw, Poland.

A25. L. Fuks, E. Gniazdowska, **P. Koźmiński**, J. Narbutt, D. Papagiannopoulou; *Tricarbonyltechnetium(I) complex with substituted propanoic acid*, Workshop on Radionuclides And Their Carriers For Medical and Industrial Applications, November 21st 2007, Warsaw, Poland.

A26. L. Fuks, E. Gniazdowska, **P. Kozminski**, J. Mieczkowski; *fac-Re^I(CO)₃⁺ Complexed by Pyridinecarboamide*, 2nd European Conference on Chemistry for Life Science, 4-8 September 2007, Wroclaw, Poland.

OTHER LECTURES AND SEMINARS

A1. **P. Koźmiński**, *Badania nad nowymi potencjalnymi radiofarmaceutykami do diagnostyki chorób cywilizacyjnych*, Seminarium Fizyki Biomedycznej, October 17th 2019, Faculty of Physics, University of Warsaw.

A2. **P. Koźmiński**, *Radiofarmacja i medycyna nuklearna*, 21 grudnia 2017, Faculty of Chemistry, University of Warsaw.

A3. **P. Koźmiński**, *Radionuklidy w medycynie : nowe perspektywy i oczekiwania*, Seminarium Fizyki Biomedycznej, October 27th 2016, Faculty of Physics, University of Warsaw.

A4. **P. Koźmiński**, Ł. Dziawer, A. Bilewicz; *Gold nanoparticles as ²¹¹At carriers for alpha radiotherapy*, JRC Enlargement and Integration Programme, 13-14 November 2014, Joint Research Centre, Ispra, Italy.

A5. **P. Koźmiński**, E. Gniazdowska; *Cząsteczki biologicznie czynne jako wektory w projektowaniu nowych radiofarmaceutyków*, Spotkanie „LIFE SCIENCES” April 9th 2014, Heavy Ion Laboratory at the University of Warsaw, Poland.

8. Information on participation in organizational and scientific committees at national or international conferences, including the applicant's function – non applicable
9. **Information on participation in the works of research teams realizing projects financed through national and international competitions, including the projects which have been completed and projects in progress, and information on the function performed in the team.**

before obtaining the doctoral degree:

- „Studies on the affinity of ghrelin towards its receptors as a function of the physicochemical properties of n-octanoyl-[Ser3]-ghrelin(1-6) labelled with technetium-99m” No. N N204 186039, supported by Ministry of Science and Higher Education MNiSW – principal investigator (PI)
- „Development of a method for the preparation of receptor diagnostic radiopharmaceutical for imaging of breast cancer of type Her-2 – Lapatinib labelled with technetium-99m” No. N R13 0150 10 supported by National Centre for Research and Development, Poland – co-investigator
- „Novel technetium and rhenium complexes with the N-heterocyclic aldehyde thiosemicarbazones - potential radiopharmaceuticals” No. N N204 141437 - co-investigator
- „New access to Tc- and Re-labelled peptides based on the “4+1” mixed- ligand approach” No. DAAD/48/2007 supported by Ministry of Science and Higher Education and German Academic Exchange Service (DAAD) - co-investigator

after obtaining the doctoral degree:

- „Production of Zr-89 and application for labeling antibodies to detect rheumatoid arthritis and gold nanoparticles for the diagnosis of sentinel nodes” No. IAEA-RC-23299-RO supported by International Atomic Energy Agency (IAEA) – co-investigator
- „Bioconjugates labeled with alpha- and beta-particles emitting radionuclides as potential radiopharmaceuticals in Targeted Radionuclide Therapy” No. NCN 2019/34/E/ST4/00080 supported by National Science Centre (NCN) – co-investigator
- „Radiolabelled peptidomimetic inhibitors of the VEGF/NRP-1 complex for imaging of pathological angiogenesis associated with early stage of malignant tumours formation” No. 2019/33/B/NZ7/02818 supported by National Science Centre (NCN) – co-investigator
- „Radiopharmaceuticals based on neurokinin-1 receptor antagonists for the diagnosis and therapy of a brain tumour – glioblastoma multiforme” No. 2017/25/B/NZ7/01896 supported by National Science Centre (NCN) – co-investigator
- „Cyclic ^{99m}Tc isolation from the gamma irradiated ^{100}Mo target” No. IAEA-RC-22521, supported by International Atomic Energy Agency (IAEA) – principal investigator (PI)
- „Cyclic ^{99m}Tc isolation from the gamma irradiated ^{100}Mo target ” No. 3882/IAEA/2018/0 supported by Ministry of Science and Higher Education – principal investigator (PI)
- „Studies on the labeling of the antibiotic cefepim with the radionuclide Ga-68” No. 2017/01/X/ST4/00925 supported by National Science Centre (NCN) - principal investigator (PI)

10. Membership in international or national organizations and scientific societies, including the functions performed by the applicant.

Polish Nucleonic Society - member

European Nuclear Society - member

11. Information on internships completed in scientific or artistic institutions, also abroad, including the place, time and duration of the internship and its character.

- Short Term Scientific Mission, COST network (COST); 16.04.2015 - 29.04.2015, Institute of Nuclear and Radiological Sciences, Technology, Energy and Safety N.C.S.R. „Demokritos” Athens, Greece
- Postgraduate certificate course Radiopharmaceutical Chemistry/Radiopharmacy Module II; 30.01.2012 - 10.02.2012, ETH Zurich, Switzerland
- Helmholtz-Zentrum Dresden-Rossendorf as the Guest Scientist, DAAD Program 02.11.2008 - 20.12.2008, Helmholtz-Zentrum Dresden-Rossendorf, Germany
- Helmholtz-Zentrum Dresden-Rossendorf as the Guest Scientist, DAAD Program 14.10.2007 - 13.12.2007, Helmholtz-Zentrum Dresden-Rossendorf, Germany
- 4th Summer School on Actinide Science and Applications, June 2007 (1 week) Institute for Transuranium Elements, Joint Research Centre, Karlsruhe, Germany
- European Project „Novel technology for controlling wine production and quality” – NovTech (HPRN-CT-2002-00186), 02.2005 - 09.2006 Instituto Pedro Nunes/University of Coimbra, Portugal

12. Membership in editorial committees and scientific boards of journals, including the functions performed by the applicant (e.g. editor-in-chief, chairman of scientific board etc.). - not applicable

13. Information on scientific or artistic works reviewed, in particular those published in international journals.

The author of the application reviewed scientific papers in the following journals:

Applied Radiation and Isotopes (1); Applied Scientific (1); Cancers (3); Contrast Media & Molecular Imaging (1); Journal of Labeled Compounds and Radiopharmaceuticals (1); Journal of Medicinal Chemistry (1); Journal of Radioanalytical and Nuclear Chemistry (4); Pharmaceutics (1); Scientific Reports (1); Tomography (1)

14. Information on participation in European or other international programmes - not applicable

European Cooperation in Science and Technology (COST)

15. Information on participation in research teams realizing projects other than those defined in section II.9 - not applicable

16. Information on membership in the teams assessing applications for financing of research projects, applications for scientific awards, applications in other competitions of scientific or didactic character - not applicable

III. INFORMATION ON COOPERATION WITH SOCIAL AND ECONOMIC ENVIRONMENT

1. List of technological works - not applicable

2. Information on cooperation with economic sector- not applicable

3. Obtaining the right of industrial property, including the national or international patents granted

- Modified cephalosporin antibiotic molecules and diagnostic radiopharmaceuticals based on these molecules for imaging bacterial infections, their preparation and use, **P. Koźmiński**, E. Gniazdowska, P. Halik, K. Żelechowska-Matysiak, **Patent No. 433215.**
- Diagnostic radiopharmaceutical for infection imaging, method for its preparation and application, **P. Koźmiński**, E. Gniazdowska, M. Chojnowski, A. Kopatys, L. Królicki, **Patent No. 238401.**
- Diagnostic radiopharmaceutical for imaging of bacterial infection and method for its preparation, **P. Koźmiński**, E. Gniazdowska **Patent No. 231312.**
- Diagnostic radiopharmaceutical for the level of cholinesterase imaging, method for its preparation and application, E. Gniazdowska, **P. Koźmiński**, E. Mikiciuk-Olasik, P. Szymański, **Patent No. 236172.**

- Modified drug substance molecule, method of its preparation, based on this molecule diagnostic or therapeutic receptor radiopharmaceutical and its application, P. K. Halik, E. Gniazdowska, **P. Koźmiński, Patent No. 23840.**
 - Diagnostic or therapeutical receptor-specific radiopharmaceutical having the affinity for the receptor Her-2, method for producing it and its application, E. Gniazdowska, **P. Koźmiński, Patent No. 229139.**
 - Therapeutic radiopharmaceutical based on gold nanoparticles marked with astatine-211 and method for producing it, Ł. Janiszewska, **P. Koźmiński, M. Pruszyński, A. Majkowska, A. Bilewicz, Patent No. 239724.**
 - Diagnostic and/or therapeutical receptor-specific radiopharmaceutical having the affinity for the receptor NK1, method for producing it and its application, E. Gniazdowska, **P. Koźmiński, Patent No. 229072.**
4. Information on implemented technologies- not applicable
 5. Information on performed expert analyses or other studies prepared on request of public institutions or entrepreneurs- not applicable
 6. Information on participation in expert and competition teams - not applicable.
 7. Information on artistic projects realized in non-artistic environment - not applicable.

IV. SCIENTOMETRIC INFORMATION

1. Information on the Impact Factor (in the fields and disciplines in which this parameter is commonly used as a scientometric index)

Data according to Journal Citation Reports (according to the year of publication)

Total IF of cycle of scientific articles: 32.292

Total IF of all scientific articles: 98.501

2. Information on the number of citations of the applicant's publications, including a separate list of self-citations.

The number of citations is based on the Web of Science database (June 6th, 2023).

The total number of citations and the number without self-citations after a slash are given.

Total number of paper citations/number without self-citations: 392/362

3. Information on h-index held

H-index = 11

According to Web of Science database (June 6th, 2023)

4. Information on the number of the points awarded by the Ministry of Science and Higher Education

Total number of the points awarded by the Ministry of Science and Higher Education (according to the year of publication)

Cycle of scientific articles: 730 points

All published scientific articles: 1743 points

Information included in section IV should also indicate the database, which was the source of information. When selecting this database specific character of the scientific field and discipline in which the candidate applies for the conferment of the post-doctoral degree of doctor habilitated should be considered as an important factor. The Council of Scientific Excellence informs that in its opinion it is recommended to provide the scientometric data; it is also a widespread practice applied by the applicants seeking academic promotion. It should be stressed, however, that scientometric data included in the applications for the commencement of promotion procedures cannot serve as a criterion for evaluation of the Candidate's scientific work for the entities awarding the PhD and post- doctoral degrees and for the Council of Scientific Excellence itself, or for the bodies running procedures for the award of a degree or title. The primary goal of these entities is expert evaluation of the scientific work of the Candidate seeking academic promotion. The decision on the conferment of the degree or title should not depend on the fact that such data is included.

.....

(Applicant's signature)